Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
Roy S. Herbst(Smilow Cancer Hospital), Masahiro Tsuboi(National Cancer Center Hospital East), Damien Urban(Tel Aviv University), Chong‐Jen Yu(National Taiwan University Hospital), Jonathan W. Goldman(University of California, Los Angeles), Ana Bolanos(Chinese Academy of Medical Sciences & Peking Union Medical College), Hữu Vĩnh Vũ(Cho Ray Hospital), Sang‐We Kim(Ulsan College), Guzel Mukhametshina(Republican Oncological Clinical Dispensary), Margarita Majem(Chinese Academy of Medical Sciences & Peking Union Medical College), Laura Bonanno(Louisiana State University), Kye Young Lee(Konkuk University Medical Center), Frances A. Shepherd(University Health Network), Marta Stachowiak(AstraZeneca (Poland)), К. К. Лактионов(Russian Cancer Research Center NN Blokhin), Charuwan Akewanlop(Siriraj Hospital), Manuel Dómine(Chinese Academy of Medical Sciences & Peking Union Medical College), Thomas John(Austin Hospital), Terufumi Kato(Taipei Veterans General Hospital), Jie Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Xiangning Huang(AstraZeneca (United Kingdom)), Filippo de Marinis(Carlo Forlanini Hospital), Christian Grohé(DRK Kliniken Berlin), Shun Lü(Shanghai Jiao Tong University)
Cited by 386
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k